L G Balakrishnan & Bros (LGBB) has recently shown steady financial performance, with notable revenue growth despite a moderate increase in operating profit. While the stock price has remained relatively flat following the latest earnings report, the company's strong gross profit margin and prudent capital expenditures indicate a solid underlying value. With favourable valuation metrics suggesting potential for price appreciation, LGBB presents an investment opportunity.
Tag: indian stocks
Lincoln Pharma: Unlocking Latent Potential
Lincoln Pharma’s current situation dictates that a small improvement in profitability going forward can significantly and positively alter the market perception about its prospects. This change in perception can be a powerful catalyst to ignite a major uptrend in the stock, provided the improvement sustains. Looking into Lincoln Pharma’s stock chart, it seems the uptrend is already in force without profitability support. Or perhaps the rising prices are presaging an improvement in profitability.
Mallcom (India): Earnings in a Downtrend. Yet the Odds seem Marginally Favourable.
Mallcom (India)’s stock could be poised for a turnaround as it approaches the end of its capital expansion phase. Still, the ongoing decline in return on equity and a precarious working capital position create uncertainty.
Force Motors: A Mind-Blowing Turnaround
The content investigates Force Motors' remarkable turnaround that led to a significant increase in profitability and valuation in recent years.
Duopoly
The Indian Automotive Glass Market is a Duopoly. High Entry Barriers, Strong Pricing Power and High Profit Margins are Key Advantages. Saint-Gobain Sekurit India Saint-Gobain Sekurit India is a dull stock, whose only notable activity over the past 25 years was its rise from ₹60 to ₹140 per share over the four years between November … Continue reading Duopoly
Amara Raja Batteries: From Nine-Bagger to a Decade of Stagnation
In the world of stock investing, the journey of Amara Raja Batteries serves as a fascinating case study of market dynamics and investor behaviour. Once celebrated for its remarkable growth, the company experienced a stunning rise from ₹100 to ₹900 per share between 2011 and 2015, showcasing its strong fundamentals and solid performance. However, the following decade brought unexpected challenges, resulting in a prolonged period of stagnation despite the business's underlying strengths. This exploration delves into the factors that shaped its rollercoaster journey, offering insights into the complexities of stock valuation and the market's unpredictability. Through this lens, we can glean valuable lessons for future investment strategies and the enduring hope that informed decisions can still lead to favourable outcomes.
Getting Your Hands Dirty
IFGL Refractories exhibits poor operating profitability, with falling profits and a precarious working capital position. Yet, three factors—stable gross profit margins, increased capital expenditures, and positive cash flow momentum—suggest potential for improved future performance.
Somany Ceramics: Financial Trauma
What happens when the price becomes more about expectations and less about fundamentals The floor tiles are often the least noticeable aspect inside a building. In the room where I sit and write this, the floor tiles are square and ivory-coloured, with white paint strokes that look like clouds on a sunny day. You are … Continue reading Somany Ceramics: Financial Trauma
Emmbi Industries: Still in Waiting
Emmbi Industries' stock, which had been trading around ₹100, recently spiked to ₹164.50 before plunging 47%. Despite an attractive valuation and growth momentum, significant risks persist, including poor profitability and high debt costs. Continuous monitoring of the stock is crucial, as its future prospects may improve despite current weaknesses.
Rolling With It
The post details the author's investment decisions regarding Vishnu Chemicals, Kovai Medical Centre, and TCPL. It outlines the case for acquiring more shares of Vishnu Chemicals, citing its improved capital structure and favourable core fundamentals despite current stagnant earnings and profitability. Conversely, the author suggests holding off on Kovai Medical Centre due to a recent decline in share price amidst moderating growth and elevated valuation. A complete exit from TCPL is recommended, driven by a significant earnings slowdown and signs of overvaluation. The analysis highlights the importance of core fundamentals in guiding investment choices.









